HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dynamic contrast-enhanced, extremity-dedicated MRI identifies synovitis changes in the follow-up of rheumatoid arthritis patients treated with rituximab.

AbstractOBJECTIVES:
The aim of this study is to assess prospectively the effect of rituximab (RTX) on MRI features of wrist joint disease in patients affected by rheumatoid arthritis (RA).
METHODS:
Ten patients (6F/4M, mean age 52.9±15.5 years) diagnosed with IgM rheumatoid factor, anti-CCP positive, RA according to the 1987 ACR criteria were treated with a single course of RTX (2 infusions of 1000 mg, 15 days apart). MRI of the dominant hand was performed with a 0.2T extremity-dedicated machine using pre and post contrast T1 weighted SE, turbo 3D, and STIR sequences at baseline, and after 4 and 24 weeks. MRI was analysed using the OMERACT-RAMRIS score and the dynamic contrast-enhanced (DCE-MRI) technique for wrist synovitis, which calculates the enhancement ratio as both rate of early enhancement (REE) and relative enhancement (RE). The corresponding ME and IRE parameters were calculated also through a computer-aided semi-automated method on the mean of three MRI slices and on a small ROI positioned in the area of maximum enhancement.
RESULTS:
DAS significantly decreased during the study period (ANOVA for repeated measures, p=0.005). The RAMRIS score did not change along the study, whereas the dynamic MRI values RE, IRE and ME on the small ROI significantly decreased. RE, but not the RAMRIS synovitis score, significantly correlated with DAS at baseline, 1 and 6 months (p=0.005, 0.04, and 0.0007, respectively).
CONCLUSIONS:
RTX confirmed good clinical efficacy, which was paralleled by a significant decrease in dynamic MRI results for wrist synovitis. On the contrary, the traditional RAMRIS measures did not change.
AuthorsMarco A Cimmino, Massimiliano Parodi, Giuseppe Zampogna, Mikael Boesen, Olga Kubassova, Francesca Barbieri, Francesco Paparo, Giacomo Garlaschi, Maurizio Cutolo
JournalClinical and experimental rheumatology (Clin Exp Rheumatol) 2014 Sep-Oct Vol. 32 Issue 5 Pg. 647-52 ISSN: 0392-856X [Print] Italy
PMID25068921 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • Antirheumatic Agents
  • Contrast Media
  • Rituximab
Topics
  • Adult
  • Aged
  • Antibodies, Monoclonal, Murine-Derived (therapeutic use)
  • Antirheumatic Agents (therapeutic use)
  • Arthritis, Rheumatoid (blood, diagnosis, drug therapy)
  • Contrast Media
  • Female
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Prospective Studies
  • Rituximab
  • Severity of Illness Index
  • Synovial Membrane (drug effects, pathology)
  • Synovitis (diagnosis, drug therapy)
  • Time Factors
  • Treatment Outcome
  • Wrist Joint (drug effects, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: